Actualités Astellas Pharma Inc (PK) - ALPMY | Actions OTCMarkets

Securities Registration (ads, Immediate) (f-6ef)

As filed with the Securities and Exchange Commission on December 21, 2017 &n...

Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)

333-153982 SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Astellas and The Chris Klug Foundation Announce Winners of the 2015 Bounce Back Award

Astellas and The Chris Klug Foundation Announce Winners of the 2015 Bounce Back Award PR Newswire NORTHBROOK, Ill. and ASPEN, Colo., June 4, 2015...

New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Mee...

New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Meeting PR...

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refr...

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid...

Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Tria...

Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial Data Presented in...

Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting

Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting PR Newswire TOKYO and...

Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers To Be...

Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers To Be Presented at 2015...

Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting

Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting PR Newswire NORTHBROOK, Ill., May 5, 2015...

Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics

Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics Exclusive Collaboration Includes Option for...

Astellas Appoints Shontelle Dodson to Lead Medical Excellence Function

Astellas Appoints Shontelle Dodson to Lead Medical Excellence Function PR Newswire TOKYO, April 6, 2015 TOKYO, April 6, 2015 /PRNewswire/...

MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia

MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia PR Newswire TOKYO and HOUSTON...

Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival Compared With Bicalutamide In St...

Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival Compared With Bicalutamide In Strive Trial PR...

Astellas Announces New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology C...

Astellas Announces New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress PR...

Astellas and Medivation Announce New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Associatio...

Astellas and Medivation Announce New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Astellas Pharma Inc (PK) (ALPMY)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

ALPMY Actualités

Securities Registration (ads, Immediate) (f-6ef)

Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)

Astellas and The Chris Klug Foundation Announce Winners of the 2015 Bounce Back Award

New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Mee...

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refr...

Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Tria...

Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting

Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers To Be...

Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting

Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics

Astellas Appoints Shontelle Dodson to Lead Medical Excellence Function

MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia

Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival Compared With Bicalutamide In St...

Astellas Announces New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology C...

Astellas and Medivation Announce New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Associatio...

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Astellas Pharma Inc (PK) (ALPMY) Actualités

Astellas Pharma Inc (PK) (ALPMY)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

ALPMY Actualités

Securities Registration (ads, Immediate) (f-6ef)

Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)

Astellas and The Chris Klug Foundation Announce Winners of the 2015 Bounce Back Award

New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Mee...

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refr...

Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Tria...

Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting

Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers To Be...

Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting

Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics

Astellas Appoints Shontelle Dodson to Lead Medical Excellence Function

MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia

Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival Compared With Bicalutamide In St...

Astellas Announces New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology C...

Astellas and Medivation Announce New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Associatio...

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application